Summary & Overview
HCPCS J8650: Nabilone, Oral, 1 mg
HCPCS Level II code J8650 designates nabilone, oral, 1 mg. Nabilone is a synthetic cannabinoid prescribed for indications such as chemotherapy-induced nausea and vomiting and other conditions where antiemetic therapy is indicated. As a drug-specific HCPCS Level II code, J8650 matters nationally because it standardizes reporting for pharmacy dispensing and clinic-administered oral medication, facilitating claims processing, utilization tracking, and policy development for payers and providers.
Key payers typically engaged in coverage and reimbursement considerations include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for nabilone, typical sites of service for billing (outpatient pharmacies and ambulatory clinics), and the payer landscape covered in the analysis. The publication highlights common billing practices, where available, along with benchmark framing and administrative considerations relevant to coding, claims submission, and benefit design. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J8650 represents Nabilone, oral, 1 mg. This code is used to report the dispensing of the oral synthetic cannabinoid medication nabilone in 1 mg units.
Service Type: Oral medication (pharmaceutical)
Typical Site of Service: Outpatient pharmacies, clinic-administered oral medication, and other ambulatory settings where oral prescriptions are dispensed or administered
Clinical & Coding Specifications
Clinical Context
A patient with chemotherapy-induced nausea and vomiting or refractory chronic neuropathic pain is prescribed oral J8650 (nabilone, 1 mg) by an oncologist or pain specialist. The typical workflow begins with an outpatient clinic visit during which the clinician documents the indication, prior therapies tried (e.g., conventional antiemetics or neuropathic pain agents), risks and benefits, and obtains informed consent. A prescription is written and the medication is dispensed by a specialty or outpatient pharmacy; for hospital inpatients, medication is administered and billed by the facility using HCPCS Level II. The patient receives counseling on dosing, side effects (dizziness, drowsiness, cognitive changes), and fall precautions. Follow-up visits occur to assess efficacy, adverse effects, and need for dose adjustment or discontinuation. Common sites of service include outpatient clinics, outpatient pharmacies, specialty pharmacies, and inpatient hospital units when administered during an admission.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | When unusually complex evaluation or management work related to medication prescribing/documentation substantially increases the service intensity |